NBNaïm Bouazza

Naïm Bouazza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Naïm Bouazza has a total of 62 co-authors. Here are the top co-authors by number of shared publications:

  • Saik Urien

    EA 7323, Université Paris Descartes Sorbonne Paris Cité, Paris, France

    8 shared publications
  • Déborah Hirt

    EA 3620 Université Paris Descartes Sorbonne Paris Cité Paris France

    5 shared publications
  • Jean-Marc Tréluyer

    EAU08, Université Paris Descartes Sorbonne Paris Cité, Paris, France; Unité de Recherche clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Tarnier, Paris, France; CIC-0901 Inserm, Cochin-Necker, Paris, France; Service de Pharmacologie Clinique, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Université Paris Descartes Sorbonne Paris Cité, Paris, France

    5 shared publications
  • Stéphane Blanche

    EAU08, Université Paris Descartes Sorbonne Paris Cité, Paris, France; Université Paris Descartes-Sorbonne Paris Cité, Institut Imagine, Paris, France

    4 shared publications
  • Frantz Foissac

    EA 3620 Université Paris Descartes Sorbonne Paris Cité Paris France

    3 shared publications
  • Pierre Frange

    Univ Paris 05, Sorbonne Paris Cite, EA 3620, Paris, France

    3 shared publications

Latest Publications

  • Evaluation of the pharmacokinetics of glibenclamide tablet given, off label, orally to children suffering from neonatal syndromic hyperglycemia

    by Naïm Bouazza, Zoubir Djerada, Claire Gozalo, Kanetee Busiah, Jacques Beltrand, Marianne Berdugo, Saik Urien, Jean-Marc Treluyer, Michel Polak

    Glibenclamide (Gb) is used in type II diabetes mellitus but also in the last 10 years, off label, in patients with neonatal syndromic hyperglycemia carrying a mutation of Kir6.2 or SUR1. No studies have reported Gb pharmacokinetics in children. In this study, oral Gb pharmacokinetics was investigated in children in order to describe the concentration time courses, the influence of covariates, and the relationships between drug concentrations and efficacy. Gb concentrations were measured in 18 children after the switch from subcutaneous insulin to oral tablets of Gb (crushed tablets for 33 % of patients). A total of 229 plasma Gb concentrations and 187 blood glucose measurements were available. A population model was developed with NONMEM. Body weight was the most significant parameter on clearance and explained a substantial part of the variability. A variant genotype of CYP2C9 (i.e., *1/*2 and *1/*3) explained also a part of the remaining variability on Gb clearance. Patients carrying these allelic variants had a clearance decreased by 45 %. A link between daily area under the curve (AUC0–24 h) and metabolic control diabetes was found. This study evaluates for the first time the pharmacokinetics of oral Gb in children and constitutes a first step towards dose individualization of this drug in a particularly vulnerable population.


  • Evaluation of antithymocyte globulin pharmacokinetics and pharmacodynamics in children

    by Naïm Bouazza, Saik Urien, Bénédicte Neven, Despina Moshous, Jennifer Nisoy, Aurélie Gabrion, Marina Cavazzana, Stéphane Blanche, Jean-Marc Tréluyer, Fabien Touzot


  • Efavirenz Concentrations and Probability of HIV Replication in Children

    by Nontiya Msc Homkham, Tim R. Cressey, Naïm Bouazza, Chulapong Chanta, Linda Aurpibul, Thition Narkbunnam, Sawitree Krikajornkitti, Nareerat Kamonpakorn, Marc Lallemant, Lily Ingsrisawang, et al.

    In 188 HIV-infected children receiving efavirenz, a lower mid-dose (C12) was associated with a higher risk of HIV-1 viral load >400 copies/mL (P = 0.03). Simulations for a normalized population receiving US Food and Drug Administration weight-band dosing predicted that 15% of children would have a C12 below target threshold (<1.0 mg/L) with a 23% risk of viral replication.


  • Evaluation of effect of impaired renal function on lamivudine pharmacokinetics

    by Naïm Bouazza, Jean‐Marc Tréluyer, Jade Ghosn, Déborah Hirt, Sihem Benaboud, Frantz Foissac, Jean‐Paul Viard, Saik Urien

    Aims: This study aimed to describe lamivudine pharmacokinetics in patients with impaired renal function and to evaluate the consistency of current dosing recommendations.Methods: A total of 244 patients, ranging in age from 18 to 79 years (median 40 years) and in bodyweight from 38 to 117 kg (median 71 kg), with 344 lamivudine plasma concentrations, were analysed using a population pharmacokinetic analysis. Serum creatinine clearance (CLCR) was calculated using the Cockcroft–Gault formula; 177 patients had normal renal function (CLCR > 90 ml min−1), 50 patients had mild renal impairment (CLCR = 60–90 ml min−1), 20 patients had moderate renal impairment (CLCR = 30–60 ml min−1), and five patients had severe renal impairment (CLCR < 30 ml min−1).Results: A two‐compartment model adequately described the data. Typical population estimates (percentage interindividual variability) of the apparent clearance (CL/F), central (Vc/F) and peripheral volumes of distribution (Vp/F), intercompartmental clearance (Q/F) and absorption rate constant (Ka) were 29.7 l h−1 (32%), 68.2 l, 114 l, 10.1 l h−1 (85%) and 1 h−1, respectively. Clearance increased significantly and gradually with CLCR. Our simulations showed that a dose of 300 mg day−1 in patients with mild renal impairment could overexpose them. A dose of 200 mg day−1 maintained an exposure close to that of adults with normal renal function. However, the current US Food and Drug Administration recommendations for lamivudine in other categories of patients (from severe to moderate renal impairment) provided optimal exposures.Conclusions: Lamivudine elimination clearance is related to renal function. To provide optimal exposure, patients with mild renal impairment should receive 200 mg day−1 instead of 300 mg day−1.


  • Concentration-response Model of Lopinavir/Ritonavir in HIV-1–infected Pediatric Patients

    by Naïm Bouazza, Saik Urien, Stéphane Blanche, Déborah Hirt, Frantz Foissac, Sihem Benaboud, Jean-Marc Tréluyer, Pierre Frange

    Objectives: The aims of this study were to analyze the viral load and CD4+ lymphocyte outcomes and the concentration-response of lopinavir/ritonavir (LPV/r) in the treatment of HIV-1-infected antiretroviral-naive children, to determine whether current dosing guidelines for LPV/r achieve C trough above 1.0 mg/L for naive patients to compare efficacy of World Health Organization 2010 and Food and Drug Administration dosing recommendations. Methods: Clinical and biologic examinations were performed before treatment, 1 month, 3 months and then every 3 months in 47 -antiretroviral-naive children who started an LPV/r-based regimen. LPV concentrations were also monitored on a routine basis, after 2 weeks of treatment initiation, between 1 and 24 hours after dosing in all children. A population pharmacokinetic-pharmacodynamic analysis was performed using an HIV dynamic model. Simulations of World Health Organization 2010 and Food and Drug Administration dosing recommendations were compared in terms of viral suppression. Results: The HIV dynamic model adequately described the data. According to the concentration-effect curve, the LPV concentration providing 90% (C-LPV90) and 95% (C-LPV95) of effect were 1.2 and 2.4 mg/L, respectively. The World Health Organization 2010 guidelines should provide a higher probability of viral success, particularly in infants. Conclusions: The C-LPV90 derived from this model supports current dosing guidelines. However, the target of 2.4 mg/L corresponding to C-LPV95 could be used to enhance the efficacy of this drug in treatment-naive children.


  • A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients

    by Naïm Bouazza, Jean-Marc Tréluyer, Philippe Msellati, Philippe Van de Perre, Serge Diagbouga, Boubacar Nacro, Hervé Hien, Emmanuelle Zoure, François Rouet, Adama Ouiminga, et al.

    Objective: The objective of this study was to develop in children an HIV dynamic model able to predict simultaneously the viral load and CD4+ lymphocyte evolutions, and to take into account, through a composite inhibition score, the relative contribution of each drug of the combination efavirenz–didanosine–lamivudine and use this score as a predictor of treatment failure in a multidrug therapy. Design: Open phase II trial (BURKINAME – ANRS 12103) registered in the ClinicalTrials.gov database ( http://clinicaltrials.gov ) with the no. NCT00122538. Methods: Forty-nine children aged from 2.5 to 15 years were administered once-daily dose of lamivudine, didanosine and efavirenz. The three drugs effect was then characterized by a composite inhibition score combining the effect of each drug, according to their site and mechanism of action and their relative contribution. Results: Efavirenz was the most potent antiretroviral and was responsible for 65% of the total effect, and then didanosine for 23% and lamivudine was the less potent with 12% of the total observed effect. An EC90 for efavirenz was determined (3.3 mg/l). AUC90 was estimated for lamivudine and didanosine: 8.4 and 1.5 mg h/l, respectively. The composite inhibition score was the best predictor of virologic failure compared with the concentrations of each drug taken independently [hazard ratio (HR) 0.6 per 10% increase, 95% confidence interval (CI) 0.41–0.88]. Conclusion: The relative contributions of three combined drugs were assessed on plasma viral load and CD4+ lymphocyte count kinetics in HIV-1-infected children. Pharmacokinetics targets have been suggested for lamivudine and didanosine. A composite inhibition score has been determined to be a high predictor of treatment failure in a multidrug therapy.


  • Open Access

    Population pharmacokinetics of clindamycin orally and intravenously administered in patients with osteomyelitis

    by Naïm Bouazza, Vincent Pestre, Vincent Jullien, Emmanuel Curis, Saïk Urien, Dominique Salmon, Jean‐Marc Tréluyer

    WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Clindamycin pharmacokinetics have been studied in adult patients. Rifampicin co‐administration could decrease clindamycin exposure.WHAT THIS STUDY ADDS• This clindamycin population analysis in patients with osteomyelitis provides useful insight into the fate of this drug and shows that clindamycin clearance increases with body weight. Moreover, this study shows a potential effect of combined rifampicin on clindamycin clearance and addresses sub‐therapeutic clindamycin concentrations in heavier patients.AIMS This study was performed to describe clindamycin, administered either orally or intravenously, concentration−time courses to patients with osteomyelitis, to study the effects of different covariates on clindamycin pharmacokinetics and to simulate an optimized administration scheme.METHODS Clindamycin concentrations were measured in 50 patients. A total of 122 plasma concentrations were available (58 from oral administration and 64 from i.v. infusion). A population pharmacokinetic model was developed with MONOLIX 4 software.RESULTS A one compartment model adequately described the data. Clindamycin clearance increased significantly with body weight (BW). The typical population estimates (interindividual variability) for clearance, volume of distribution and absorption rate constant were 16.2 l h−1 (0.39), 70.2 l and 0.92 h−1, respectively. The bioavailability of the oral form was estimated to be 87.6%. According to BW, theoretical doses needed to reach a Cmin of 2 mg l−1 were then calculated.CONCLUSIONS The current recommendation of 600 mg three times daily seems to be effective up to 75 kg but the dose should be raised to 900 mg three times daily thereafter. These assumptions should be prospectively confirmed.


  • Population Pharmacokinetics of Tenofovir in HIV-1–Infected Pediatric Patients

    by Naïm Bouazza, Saik Urien, Déborah Hirt, Pierre Frange, Elisabeth Rey, Sihem Benaboud, Frantz Foissac, Stéphane Blanche, Jean-Marc Tréluyer

    Objectives To evaluate the pharmacokinetics of tenofovir in children and the influence of covariates [body weight (BW), age, cotreatments]. The main goal was then to suggest for the first time the dose of tenofovir disoproxil fumarate (TDF) to give in children. Design/Methods Tenofovir concentrations were monitored on a routine basis and measured in 93 children aged 5 to 18 years; 283 tenofovir plasma concentrations were used to perform a population pharmacokinetic analysis. Results A 2-compartment model adequately described the data. A BW allometric scaling was used; and the typical population estimates (interindividual variability), standardized for 70 kg, for apparent clearance, central and peripheral volume of distribution, intercompartmental clearance, and absorption rate constant, were 59.8 L·h-1 (0.48), 386 L (1.39), 666 L, 92.8 L·h-1 and 0.43 h-1, respectively. TDF clearance increased significantly with BW and decreased with lopinavir/ritonavir (LPV/r) coadministration, thus these factors were used to propose doses for children. Dosing scheme, according BW and LPV/r coadministration were simulated to produce the same 24-hr exposure as adults after 300-mg TDF dose. Conclusions Children without LPV/r should receive: 150 mg TDF from 20 to 30 kg, 225 mg TDF from 30 to 40 kg, and the adult dosage of 300 mg TDF over 40 kg. To avoid risk of renal toxicity, TDF dose should be decreased when coadministrated with LPV/r, children should receive 150 mg TDF from 20 to 40 kg, 225 mg TDF from 40 to 55 kg, and the adult dosage of 300 mg TDF over 55 kg.


  • Developmental Pharmacokinetics of Lamivudine in 580 Pediatric Patients Ranging from Neonates to Adolescents

    by Naïm Bouazza, Déborah Hirt, Stéphane Blanche, Pierre Frange, Elisabeth Rey, Jean-Marc Tréluyer, Saik Urien

    Lamivudine concentration-time courses were described for a very large range of ages to study the effects of body weight and maturation on lamivudine pharmacokinetics and to check the consistency of dosing recommendations. Lamivudine concentrations were monitored on a routine basis to produce concentrations similar to the known values in adults. Concentrations were measured in 580 children from 2 days to 18 years old. A total of 2,106 plasma lamivudine concentrations were measured, and a population pharmacokinetic analysis was performed using the stochastic approximation expectation maximization algorithm implemented in MONOLIX 3.1 software. A two-compartment model adequately described the data. After standardization for a mean standard body weight by using an allometric model, age also had a significant effect on clearance maturation. Typical population estimates (percent interindividual variability) standardized for 70 kg of the apparent clearance, including central and peripheral volumes of distribution, intercompartmental clearance, and absorption rate constant, were 31 liters·h−1(32%), 76.4 liters (77%), 129 liters, 5.83 liters·h−1, and 0.432 h−1, respectively. According to the model, elimination clearance (liters/h/70 kg) increases gradually during the first years of life. Theoretical doses needed to reach the range of 24 h of exposure observed in adults were calculated: to be closer to adult exposure, children should receive 4 mg/kg/day from birth to 8 weeks of age, 5 mg/kg/day from 8 to 16 weeks of age, 6 mg/kg from 16 to 25 weeks of age, 8 mg/kg/day from 25 weeks of age to 14 kg of body weight, 150 mg/day from 14 to 25 kg of body weight, 225 mg/day from 25 to 35 kg of body weight, and 300 mg/day thereafter.


  • Open Access

    Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients

    by Naïm Bouazza, Jean-Marc Tréluyer, Chris Ottolenghi, Saik Urien, Georges Deschenes, Daniel Ricquier, Patrick Niaudet, Bernadette Chadefaux-Vekemans

    Nephropathic cystinosis is an autosomal recessive disorder resulting in an impaired transport of cystine trough the lysosomal membrane causing an accumulation of free cystine in lysosomes. The only specific treatment for nephropathic cystinosis is cysteamine bitartrate. This study was aimed to describe the relationship between cysteamine plasma concentrations and white blood cell cystine levels, and to simulate an optimized administration scheme to improve the management of patients with cystinosis.